Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Dolutegravir, Lamivudine, and Abacavir in a Real-Life Cohort of HIV-Infected Adults

Efficacy and safety of dolutegravir plus lamivudine as a first-line regimen in clinical practice

(2021) Arturo Ciccullo et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Risks and benefits of reducing the number of drugs to treat HIV-1 infection

(2021) Julen Cadiñanos et al.   Expert Opinion On Drug Safety

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

(2021) Chloe Orkin et al.   Lancet HIV

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide–Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study

(2020) Jean van Wyk et al.   CLINICAL INFECTIOUS DISEASES

Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study

(2020) Francesca Lombardi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

(2020) Susan Swindells et al.   NEW ENGLAND JOURNAL OF MEDICINE

DOLAMA study

(2019) Carmen Hidalgo-Tenorio et al.   MEDICINE

Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis

(2019) Oghenowede Eyawo et al.   BMJ Open

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection

(2019) Pedro Cahn et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Risk of Cardiovascular Disease Associated With Exposure To Abacavir Among Individuals With HIV: A Systematic Review And Meta-analyses Of Results From Seventeen Epidemiologic Studies

(2018) Kunchok Dorjee et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

New Strategies of ARV: the Road to Simplification

(2018) Rosa de Miguel Buckley et al.   Current HIV/AIDS Reports

Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)

(2018) Véronique Joly et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

(2018) Pedro Cahn et al.   LANCET

Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study

(2017) Pedro Cahn et al.   Journal of the International AIDS Society

Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?

(2016) Sean G. Kelly et al.   DRUGS

Future challenges for clinical care of an ageing population infected with HIV: a modelling study

(2015) Mikaela Smit et al.   LANCET INFECTIOUS DISEASES

A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results

(2015) Tessa Kennedy-Martin et al.   Trials

The history of antiretroviral therapy and of its implementation in resource-limited areas of the world

(2012) Stefano Vella et al.   AIDS